Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

Table 1

Patient characteristics.

Characteristics	All patients (26)
Median age, years (range)	38 (range: 25–68)
Gender (%)
Female	11 (42)
Male	15 (58)
Median baseline KPS	80 (70–100)
Histotype (%)
GBM	13 (50)
Anaplastic astrocytoma	7 (27)
Anaplastic oligodendroglioma	2 (8)
Anaplastic oligoastrocytoma	4 (15)
Prior surgery (%)
Biopsy	11 (42.5)
Partial resection	11 (42.5)
Total resection	4 (15)
Prior radiotherapy	26 (100)
Second surgery	7 (27)
Prior lines of chemotherapy (%)
1	26 (100)
2	11 (42)
Type of prior chemotherapy (%)
TMZ	26 (100)
PCV	4 (15)
MGMT gene promoter methylation status (%)
Evaluable	19 (73)
Unmethylation	10 (53)
Methylation	9 (47)

KPS: Karnofsky performance status; TMZ: temozolomide; PCV: procarbazine, carmustine, and vincristine; MGMT: methylguanine methyltransferase.